Metabolomic Biomarkers to Predict and Diagnose Cystic Fibrosis Pulmonary Exacerbations: A Systematic Review.

ABSTRACT:

Introduction

Metabolomics is an emerging area of research and has the potential to identify clinical biomarkers for predicting or diagnosing cystic fibrosis (CF) pulmonary exacerbations (PEx).

Objective

To identify clinically promising metabolites across different sample sources that can be used to predict or diagnose PEx in CF.

Evidence review

Searches for original literature were completed through EMBASE, MEDLINE, and all databases on the Web of Science with no restrictions on language or publication date. Gray literature was collected through Google Scholar. Additional studies were obtained by contacting authors and searching reference lists of candidate papers. The patient population included individuals with CF. Studies involving patients who underwent lung trans

SUBMITTER: Nguyen AV 

PROVIDER: S-EPMC9192952 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature